BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10117769)

  • 1. Multi-purpose evaluation of H2-antagonist usage.
    Gianarkis D
    Hosp Formul; 1992 May; 27(5):527-30, 532. PubMed ID: 10117769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical appropriateness, therapeutic equivalence, and cost of conversion of H2 antagonist therapy.
    Kitrenos JG; Brown DR; Letting DJ; Rotella DL
    Hosp Formul; 1993 Jan; 28(1):86-8, 91, 95-6. PubMed ID: 10123271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidisciplinary education ensures successful formulary conversion.
    Barfield PS; Amerson AB
    Hosp Formul; 1991 Nov; 26 Suppl D():28-9. PubMed ID: 10136563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational selection of H2-receptor antagonists for the hospital formulary. Roundtable discussion.
    Keeffe EB; Harper JM; LeMay A; Sherrin TP; Siepler JK
    Hosp Formul; 1991 Nov; 26 Suppl D():13-9. PubMed ID: 10136560
    [No Abstract]   [Full Text] [Related]  

  • 5. Formulary designation of cimetidine as the primary intravenous histamine H2-receptor antagonist.
    Berkowitz HS
    Am J Hosp Pharm; 1992 Jan; 49(1):134-5. PubMed ID: 1349201
    [No Abstract]   [Full Text] [Related]  

  • 6. Retrospective analysis of formulary restriction demonstrates significant cost savings.
    Wetmore RW; Jennings RH
    Hosp Formul; 1991 Nov; 26 Suppl D():30-2. PubMed ID: 10136564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Criteria-based DUE aids in selection of preferred agent.
    Drea EJ
    Hosp Formul; 1991 Nov; 26 Suppl D():25-7. PubMed ID: 10136562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiulcer therapy: an exercise in formulary management.
    Foulke GE; Siepler J
    J Clin Gastroenterol; 1990; 12 Suppl 2():S64-8. PubMed ID: 1978846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategy for developing a safe and cost-effective H2-receptor antagonist program.
    Quercia RA; Chow MS; Jay GT; Quintiliani R
    Hosp Formul; 1991 Nov; 26 Suppl D():20-4. PubMed ID: 10136561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of concurrent monitoring and a preprinted note to modify prescribing of i.v. cimetidine and ranitidine in a teaching hospital.
    Dannenhoffer MA; Slaughter RL; Hunt SN
    Am J Hosp Pharm; 1989 Aug; 46(8):1570-5. PubMed ID: 2773962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing costs with formulary limitation of H2-receptor antagonists in a community hospital.
    Coppola P
    Hosp Pharm; 1991 Feb; 26(2):126-9, 142. PubMed ID: 10136547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of H2-receptor antagonists in children.
    Dimand RJ
    DICP; 1990 Nov; 24(11 Suppl):S42-6. PubMed ID: 2270695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug usage evaluation: H2-receptor antagonist use in 30 hospitals.
    Kowalsky SF; Hamilton RA; Figge HL
    Hosp Formul; 1991 Sep; 26(9):725-6, 732, 734-6 passim. PubMed ID: 10114004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementing therapeutic interchange of intravenous famotidine for cimetidine and ranitidine.
    Oh T; Franko TG
    Am J Hosp Pharm; 1990 Jul; 47(7):1547-51. PubMed ID: 2114789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with a two-tiered therapeutic interchange policy.
    Rich DS
    Am J Hosp Pharm; 1989 Sep; 46(9):1792-8. PubMed ID: 2572167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative evaluation of cimetidine and ranitidine.
    Zimmerman TW; Schenker S
    Ration Drug Ther; 1985 Apr; 19(4):1-7. PubMed ID: 2932770
    [No Abstract]   [Full Text] [Related]  

  • 17. Tri-hospital formulary management: a joint effort to standardize therapy and reduce costs.
    Kile DM; McGrath ME; Schindel LP
    Hosp Formul; 1987 Feb; 22(2):176, 178, 181. PubMed ID: 10280289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacoeconomic analysis of IV H2-receptor antagonist use in 40 hospitals.
    Segal R; Oh T; Ben-Joseph R; Russell WL
    Hosp Formul; 1994 May; 29(5):379-82, 388-91. PubMed ID: 10136601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision analysis applied to selection of histamine H2-receptor antagonists for the formulary.
    Calvo MV; Fruns I; Domínguez-Gil A
    Am J Hosp Pharm; 1990 Sep; 47(9):2002-6. PubMed ID: 1977316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P & T Committee interview: Establishing and maintaining a dynamic formulary.
    Rostand S; Lazarus H
    Hosp Formul; 1988 Jan; 23(1):48-53. PubMed ID: 10285373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.